Table 1.
Variable | No. | Percent | |
---|---|---|---|
Age (year) | < 60 | 35 | 70% |
≥ 60 | 15 | 30% | |
Sex | Female | 49 | 98% |
Male | 1 | 2% | |
Molecular type | Luminal A | 10 | 20% |
Luminal B | 6 | 12% | |
HER2 | 19 | 38% | |
TN | 15 | 30% | |
CAF pattern | Type A | 24 | 48% |
Type B | 20 | 40% | |
Type C | 6 | 12% | |
PDGFR-β | Low | 27 | 54% |
High | 23 | 46% | |
α-SMA | Low | 27 | 54% |
High | 23 | 46% | |
Tumor location | Supratentorial | 37 | 74% |
Infratentorial | 13 | 26% | |
Extracranial Mets | Absent | 12 | 24% |
Present | 38 | 76% | |
BM symptom | Mild to moderate | 31 | 62% |
Severe | 19 | 38% | |
KPS | ≥ 80 | 32 | 64% |
< 80 | 18 | 36% | |
BM multiplicity | Single | 24 | 48% |
Multiple | 26 | 52% | |
BM development | Metachronous | 49 | 98% |
Synchronous | 1 | 2% | |
BM size | < 4 cm | 22 | 44% |
≥ 4 cm | 28 | 56% | |
Peritumoral edema | Mild to moderate | 27 | 54% |
Severe | 23 | 46% | |
Tumor nature | Solid | 27 | 54% |
Cystic or mixed | 23 | 46% | |
Resection degree | Gross total | 38 | 76% |
Partial to subtotal | 12 | 24% | |
Postoperative RT/GKS | Absent | 16 | 32% |
Present | 34 | 68% |
BC, breast cancer; BM, brain metastasis; α-SMA, alpha-smooth muscle actin; CAF, cancer-associated fibroblast; GKS, gamma knife radiosurgery; KPS, Karnofsky performance score; Mets, metastasis; PDGFR-β, platelet-derived growth factor receptor-beta; RT, radiation treatment; TN, triple negative